Details of the Drug

General Information of Drug (ID: DM0ZMNI)

Drug Name

REGN6569

Indication

Disease Entry	ICD 11	Status	REF
Squamous head and neck cell carcinom	2D60.0	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Activation-inducible TNFR family receptor (TNFRSF18)	TTG6LA7	TNR18_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Squamous head and neck cell carcinom

ICD Disease Classification

2D60.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Activation-inducible TNFR family receptor (TNFRSF18)	DTT	TNFRSF18	2.39E-03	-0.54	-0.7

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04465487) Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.